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Abstract
Background: Mycobacterium abscessus is a rapidly growing Mycobacterium that is a common water contaminant in
the environment. We report a case of M. abscessus infection with band erosion following laparoscopic gastric
banding.
Case presentation: A 34-year-old woman developed insidiously progressing abdominal distension over a period of
1 year associated with abdominal pain, fatigue, night sweating and anorexia 4 years after laparoscopic gastric
banding for obesity. Investigation revealed significant ascites with caseating granuloma in peritoneal biopsies from
which M. abscessus was isolated. Band erosion with infection and multiple abdominal adhesions were confirmed
during laparoscopic removal of the gastric band. To the best of our knowledge, this is the first reported case of
M. abscessus infection after laparoscopic gastric banding surgery. We discuss the possible sources of infection, its
indolent presentation, and therapeutic challenges.
Conclusion: It is important to consider environmentally acquired infection in patients with signs and symptoms of
infection in the presence of surgical prosthesis.
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Background
Mycobacterium abscessus is a rapidly growing Mycobacter-
ium that is a common water contaminant. Clinical disease
due to M. abscessus most often presents as chronic lung
disease, or as skin, bone or soft-tissue infection following
trauma [1-3]. Disseminated disease has been reported in
immunocompromised patients [4]. Although nosocomial
infections associated with infected prostheses have been
reported, such as otitis media following tympanostomy
tube placement, peritoneal catheter-related peritonitis,
infection after breast augmentation and septic arthritis
with joint prosthesis [5-8], there are no reported cases
associated with laparoscopic gastric banding devices. In-
fections with other mycobacteria other than tuberculosis
(MOTT) have been reported after gastric banding [9-11].
This report describes a case of M. abscessus peritonitis in
a patient with a history of laparoscopic gastric banding
surgery. We discuss the possible sources and therapeutic
challenges of infection, and highlight environmentally
acquired infection in patients with signs and symptoms of
infection in the presence of surgical prosthesis.
Case presentation
A 34-year-old woman presented with insidiously
progressing abdominal distension of one year’s duration.
Review of systems was significant for colicky abdominal
pain, fatigue, night sweating and anorexia. The woman
had no history of fever, jaundice, tuberculosis contact,
weight loss or lower limb swelling. She was not on any
medications. Her surgical history included laparoscopic
gastric banding surgery for obesity (body mass index = 50;
weight, 120 kg) 4 years earlier without complications. The
patient had received normal saline injections through an
injection port underneath the skin in the first 2 years after
surgery to tighten the band. She had lost 50 kg since sur-
gery. She was single, a graphic designer, and a smoker.
Her menses were regular and there was no family history
of malignancy. The patient’s blood pressure on admission
was 110/78 mmHg, her pulse was 82 bpm, her respiratory
rate was 18 breaths per minute, and her temperature was
36.8°C. There were no palpable lymph nodes, pallor, jaun-
dice, or other stigmata of chronic liver disease. Abdominal
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examination revealed a distended soft lax abdomen, a
tender epigastrium on deep palpation with no guarding or
rigidity, positive shifting dullness, and otherwise normal
findings. Complete blood count and hepatic, coagulation
and renal profiles were within normal limits and there was
no proteinuria. Abdominal ultrasound showed moderate
to severe ascites and normal liver size and echogenicity
with a patent portal vein. Tumor marker CA 125 was
high. Abdominal computed tomography showed large as-
cites with prominent ovaries bilaterally but no definitive
mass or lymphadenopathy. Diagnostic and therapeutic
paracentesis was performed, draining 7 l. Fluid analysis
showed low serum ascites albumin gradient. Cytology
was negative for malignant cells. Laparoscopic periton-
eal and ovarian biopsies showed caseating granulomata
without malignant cells or acid-fast bacilli. Acid-fast ba-
cilli culture of the ascitic fluid and of peritoneal and
ovarian biopsies grew Mycobacterium species in both
Middlebrook 7H9 Broth (BACTEC MGIT 960 system)
and Lowenstein-Jensen after one week of incubation.
Colonies appeared smooth and greyish in Lowenstein-
Jensen at a temperature of 28°C and 36°C with positive
arylsulfatase test and negative ProbeTec ET test.
The patient began treatment for rapidly growing Myco-
bacterium infection with clarithromycin, rifampicin,
moxifloxacin and ethambutol. The isolate was identified
by Line Probe Assay INNO-LiPA MYCOBACTERIA V2
(Innogenetics, Ghent, Belgium) as M. chelonae complex
/abscessus. The Clinical Microbiology Laboratory at
Mayo Clinic used DNA sequencing and real-time
PCR, per the Clinical and Laboratory Standards Insti-
tute (CLSI) [12],to confirm that the isolate was
M. abscessus, subspecies abscessus. Breakpoint suscep-
tibility testing was performed using the CLSI
recommended broth microdilution MIC method with
nine drugs (amikacin, tobramycin, trimethoprim-
sulfamethoxazole, cefoxitin, imipenem, linezolid, doxy-
cycline/minocycline, clarithromycin and ciprofloxacin)
[Table 1]. Breakpoints for tigecycline have not been
evaluated by the CLSI for mycobacteria [12]. The
isolate was resistant to quinolones and rifampicin, and
was susceptible to clarithromycin and amikacin. Ri-
fampicin and moxifloxacin were discontinued and
amikacin was started along with ethambutol and
clarithromycin. Laparoscopic surgery for gastric band
removal was performed. Significant inflammation with
dense adhesions surrounding the entire band and black
discoloration of the gastric band were noted during the
procedure (Figure 1). Adhesiolysiswas performed and
the band was removed. Tissue from the inflammation
around the band showed granulomata and culture was
positive for M. abscessus. Additional antimicrobials
with potential activity against M. abscessus were added
sequentially (imipenem, tigecycline and linezolid), but
the patient could not tolerate them for various reasons.
After 5 months of clarithromycin and ethambutol
Figure 1 Infected gastric band. A: Adhesion around the gastric band. B: Fluid from the gastric band. C&D: Black discoloration of the
gastric band.
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treatment supplemented with amikacin for the first
2 months, the patient had an excellent recovery and
become completely asymptomatic.
Discussion
M. abscessus is a rapidly growing Mycobacterium that is a
common water contaminant. Human disease is suspected
to result from environmental exposure. Literature review
on Mycobacterium infections after laparoscopic gastric
banding identified three reported cases of M. fortuitum in-
fections. The first case was a young patient who developed
peritonitis within a few days after gastric banding surgery.
The other two patients had laparoscopic gastric banding
procedures on the same day and in the same operating
room [10,11]. M. bolletii infection was isolated in another
reported case after revision of gastric banding [9]. To our
knowledge this is the first case of M. abscessus infection
following laparoscopic gastric banding.
We believe that the most likely sources of Mycobac-
terium were the gastric band itself, the surgical envi
ronment or contaminated injected saline. Although
M. abscessus was isolated from the inflamed tissue
around the gastric band, unfortunately no microbio-
logical culture was sent from either the gastric band it-
self or the saline. The patient developed abdominal
distension 4 years after gastric banding and had three
saline band injections. Our patient had a delayed pres-
entation 4 years after surgery, while in the other
reported cases of Mycobacterium-infected gastric bands,
infection occurred within 2 months of surgery.
Our patient developed infection 4 years post-surgery,
suggesting an indolent course of this organism. This
course is similar to a case of M. abscessus peritonitis
that occurred in the 3rd year after peritoneal catheter
placement and after 2 years of persistent isolation of
M. abscessus from the catheter exit site without initial
evidence of peritonitis [6].
M. abscessus isolates are uniformly resistant to stand-
ard antituberculosis agents. M. abscessus is susceptible
to clarithromycin (100%), amikacin (90%), cefoxitin
(70%), imipenem, linezolid, clofazimine and tigecycline
[13]. The role of drug susceptibility testing in the choice
of agents for antimicrobial treatment of M. abscessus re-
mains a subject of debate. There are important discrep-
ancies between drug susceptibility measured in vitro and
the activity of the drug observed in vivo, partly deriving
from laboratory technical issues, and no clear standard-
ized treatment method exists. Until the relationship
between in vitro susceptibility and clinical response of
M. abscessus to antimicrobial drugs is better understood
and clarified, antibiotic susceptibility testing of all clinic-
ally significant isolates is recommended.
Treatment regimens include clarithromycin for 6 months
in cases of skin and soft tissue infections and at least
12 months for pulmonary infections. For serious dissemi-
nated infections combination therapy with amikacin
plus imipenem or cefoxitin for the first 2–6 weeks usu-
ally produces clinical and microbiologic improvement
[13]. Regarding M. abscessus infection and prosthesis, a
small number of previously reported cases exist. These
include chronic otitis media after tympanostomy tube
placement, peritonitis with peritoneal catheter, mastitis
after breast augmentation, and septic arthritis with
prosthetic joints. Almost all cases required removal of
prostheses and antibiotic therapy based on in vtro
sensitivity for an average duration of 5–6 months, with
at least 4–6 weeks of parenteral antibiotics [5-8].
This case highlights an environmentally acquired infec-
tion after laparoscopic gastric banding. Physicians need to
consider MOTT as a cause of infection in the presence of
surgical prosthesis. Treatment should include removal of
any infected prosthesis and the use of appropriate antibi-
otics based on susceptibility testing.
Conclusion
Our case highlights the potential therapeutic complica-
tion of Mycobacterium infection in association with lap-
aroscopic gastric banding procedures. When treating
patients with signs and symptoms of infection and a his-
tory of surgical prosthesis, clinicians should consider
MOTT as potential pathogens. Once diagnosed, initial
treatment should include appropriate antibiotics selected
based on susceptibility results as well as the removal of
any infected materials.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the Editor of this journal.
Table 1 Broth microdilution interpretive criteria for
rapidly growing mycobacteria
MIC (μg / mL) for category
Antimicrobial agent Susceptible Intermediate Resistant
Amikacin ≤ 16 32 ≥ 64
Cefoxitin ≤ 16 32–64 ≥ 128
Ciprofloxacin ≤ 1 2 ≥ 4
Clarithromycin ≤ 2 4 ≥ 8
Doxycycline ≤ 1 2–8 ≥ 16
Imipenem ≤ 4 8 ≥ 16
Linezolid ≤ 8 16 ≥ 32
Sulfamethoxazole ≤ 32 - ≥ 64
Tobramycin ≤ 4 8 ≥ 16
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